World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
91
Citations
35814
World Ranking
11628
National Ranking
5964

Barry J. Byrne publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Barry J. Byrne sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 477 publications — 54th percentile

54% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Barry J. Byrne D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Barry J. Byrne sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 91 D-Index — 43rd percentile

43% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Barry J. Byrne is affiliated with the University of Florida in the United States. Their research spans multiple fields within medicine and biomedical sciences, focusing extensively on gene therapy and genetic disorders.

The primary areas of study for this scientist include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Within these broader fields, their work covers several specialized subfields:

  • Molecular Biology
  • Genetics
  • Physiology
  • Rheumatology
  • Psychiatry and Mental Health

Barry J. Byrne's research topics highlight specific biomedical challenges and therapeutic strategies, notably:

  • Lysosomal Storage Disorders Research
  • Glycogen Storage Diseases and Myoclonus
  • Virus-based Gene Therapy Research
  • Child Nutrition and Feeding Issues
  • Neurogenetic and Muscular Disorders Research
  • Muscle Physiology and Disorders
  • Carbohydrate Chemistry and Synthesis

The scientist has contributed to multiple recent papers illustrating these focuses. Selected recent publications include:

  • Current Clinical Applications of In Vivo Gene Therapy with AAVs, 2020, Molecular Therapy
  • Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency, 2021, Molecular Therapy
  • Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial, 2021, The Lancet Neurology
  • Management of Neuroinflammatory Responses to AAV-Mediated Gene Therapies for Neurodegenerative Diseases, 2020, Brain Sciences
  • Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies, 2023, Journal of Clinical Investigation

Barry J. Byrne often collaborates with other researchers, frequently working alongside:

  • Manuela Corti
  • Priya S. Kishnani
  • Benedikt Schoser
  • Tahseen Mozaffar
  • David D. Fuller

The scientist's research outputs have appeared primarily in these publication venues:

  • Molecular Therapy
  • Neuromuscular Disorders
  • Molecular Genetics and Metabolism
  • Physiology
  • Neurology

Best Publications

  • Human Mesenchymal Stem Cells Differentiate to a Cardiomyocyte Phenotype in the Adult Murine Heart

    Catalin Toma;Mark F. Pittenger;Kevin S. Cahill;Barry J. Byrne

  • Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield

    S Zolotukhin;B J Byrne;E Mason;I Zolotukhin

  • Treatment of Leber Congenital Amaurosis Due to RPE65 Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results of a Phase I Trial

    William W. Hauswirth;Tomas S. Aleman;Shalesh Kaushal;Artur V. Cideciyan

  • Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy.

    Jill W. Miller;Carl R. Urbinati;Patana Teng-umnuay;Myrna G. Stenberg

  • Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neovascularization

    Maria B. Grant;W. Stratford May;Sergio Caballero;Gary A. J. Brown

  • Recombinant human acid α-glucosidase Major clinical benefits in infantile-onset Pompe disease

    P. S. Kishnani;D. Corzo;M. Nicolino;B. Byrne

  • Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics

    Artur V. Cideciyan;Tomas S. Aleman;Sanford L. Boye;Sharon B. Schwartz

  • Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein

    Paul D. Kessler;Gregory M. Podsakoff;Xiaojuan Chen;Susan A. McQuiston

  • Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years

    Samuel G. Jacobson;Artur V. Cideciyan;Ramakrishna Ratnakaram;Elise Heon

  • Pompe disease diagnosis and management guideline

    Priya S Kishnani;Robert D Steiner;Deeksha Bali;Kenneth Berger

  • Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors.

    Sergei Zolotukhin;Mark Potter;Irene Zolotukhin;Yoshihisa Sakai

  • Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy.

    Jerry R. Mendell;Nathalie Goemans;Linda P. Lowes;Lindsay N. Alfano

  • Current Clinical Applications of In Vivo Gene Therapy with AAVs.

    Jerry R. Mendell;Jerry R. Mendell;Samiah A. Al-Zaidy;Louise R. Rodino-Klapac;Kimberly Goodspeed

  • Antibody-Based Sensors: Principles, Problems and Potential for Detection of Pathogens and Associated Toxins

    Barry Byrne;Edwina Stack;Niamh Gilmartin;Richard O'Kennedy

  • Recombinant Adeno-Associated Virus Serotype 9 Leads to Preferential Cardiac Transduction In Vivo

    Christina A. Pacak;Cathryn S. Mah;Bijoy D. Thattaliyath;Thomas J. Conlon

  • Human RPE65 Gene Therapy for Leber Congenital Amaurosis: Persistence of Early Visual Improvements and Safety at 1 Year

    Artur V. Cideciyan;William W. Hauswirth;Tomas S. Aleman;Shalesh Kaushal

  • Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy

    Mark L. Brantly;Jeffrey D. Chulay;Lili Wang;Christian Mueller

  • Effect of Intracoronary Delivery of Autologous Bone Marrow Mononuclear Cells 2 to 3 Weeks Following Acute Myocardial Infarction on Left Ventricular Function The LateTIME Randomized Trial

    Jay H. Traverse;Timothy D. Henry;Stephen G. Ellis;Carl J. Pepine

  • Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors

    Sihong Song;Michael Morgan;Tamir Ellis;Amy Poirier

  • Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease

    Marc Nicolino;Barry Byrne;J. E. Wraith;Nancy Leslie

Frequent Co-Authors

David D. Fuller
David D. Fuller University of Florida
Terence R. Flotte
Terence R. Flotte University of Massachusetts Chan Medical School
Priya S. Kishnani
Priya S. Kishnani Duke University
Roland W. Herzog
Roland W. Herzog Indiana University
Nicholas Muzyczka
Nicholas Muzyczka University of Florida
Sergei Zolotukhin
Sergei Zolotukhin University of Florida
Richard O'Kennedy
Richard O'Kennedy Hamad bin Khalifa University
William W. Hauswirth
William W. Hauswirth University of Florida
Benedikt Schoser
Benedikt Schoser Ludwig-Maximilians-Universität München
Richard S. Finkel
Richard S. Finkel St. Jude Children's Research Hospital

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re exploring careers in medicine but want flexible or alternative pathways, several related online degrees and certifications can open doors in the healthcare field. For example, those interested in working behind the scenes in healthcare may consider programs from medical billing and coding schools online with financial aid, which provide in-demand technical skills with reduced financial barriers.

Many students are also drawn to nursing as a rewarding and high-demand profession. There are now nursing schools that don't require teas or hesi exams, making the admissions process more accessible for prospective nurses.

For those aiming at leadership or administrative roles within healthcare, pursuing a health administration degree online provides accelerated options to advance your career. Alternatively, licensed RNs seeking career growth can look into adn to fnp bridge programs to become Family Nurse Practitioners.

Each pathway offers unique opportunities and flexibility, so you can find an option that aligns with your career goals and personal circumstances.

Best Scientists Citing Barry J. Byrne

Trending Scientists

Recently Published Articles